نتایج جستجو برای: dutasteride

تعداد نتایج: 380  

2013
Dong Il Kang Jae Il Chung

The key enzyme in the androgen synthesis and androgen receptor pathways is 5α-reductase (5-AR), which occurs as three isoenzymes. Types I and II 5-ARs the most important clinically, and two different 5-AR inhibitors (5-ARIs), finasteride and dutasteride, have been developed. Several urology associations have recommended and upgraded the use of 5-ARIs for an enlarged prostate with lower urinary ...

2011
Byung Hoon Chi Sae Chul Kim

PURPOSE Sexual adverse events (AEs), a major cause for discontinuing 5α-reductase inhibitor (5ARI) therapy for benign prostatic hyperplasia (BPH), are known to occur most frequently early in therapy and appear to decline over time. The aim of this study was to investigate the changes in sexual function occurring with dutasteride treatment during a 1-year follow-up period in Korean men. MATERI...

2015
Eddy J. Chen Adam G. Sowalsky Shuai Gao Changmeng Cai Olga Voznesensky Rachel Schaefer Massimo Loda Lawrence D. True Huihui Ye Patricia Troncoso Rosina L. Lis Philip W. Kantoff Robert B. Montgomery Peter S. Nelson Glenn J. Bubley Steven P. Balk Mary-Ellen Taplin

Purpose: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (AR) identified previously in flutamideresistant tumors. Therefore, we sought to determine if CYP17A1 inhibitor treatment selects for progesterone...

2010
Sung Woon Park Chul Sung Kim Gilho Lee

PURPOSE Studies of genetic variation in the prostate-specific antigen (PSA) gene have improved the diagnostic accuracy of PSA for diagnosing prostate diseases in Caucasians. However, the reference ranges and pharmacokinetics of PSA differ significantly according to race. Therefore, we evaluated the association between genetic variations in the PSA promoter area and benign prostatic hyperplasia ...

2015
Yi-Ping Zhu Bo Dai Hai-Liang Zhang Guo-hai Shi Ding-Wei Ye

BACKGROUND The ability of 5α-reductase inhibitors (5ARIs) to decrease blood loss during transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH) remains controversial. We aimed to conduct a meta-analysis of all randomized controlled trials (RCTs) to establish the role of 5ARI use prior to TURP. METHODS We searched studies from the electronic databases PubMed, Emba...

Journal: :BJU international 2006
François Desgrandchamps Stephane Droupy Jacques Irani Christian Saussine Andrea Comenducci

OBJECTIVE To assess the improvements in symptoms, quality of life (QoL), discomfort and satisfaction in patients with symptomatic benign prostatic hyperplasia (BPH) treated with dutasteride in clinical practice. PATIENTS AND METHODS In a prospective, multicentre open-label study, we evaluated the efficacy and safety in clinical practice of dutasteride, 0.5 mg/day for 24 weeks, in patients wit...

2014

A. Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin) B. Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin) C. Interstitial laser coagulation of the prostate (ILCP) D. Laser prostatectomy E. Laser based procedures including contact laser ablation of the prostate (CLAP), holmium laser procedures of the prostate (HoLAP, ...

2018
Michael V. Fiandalo John J. Stocking Elena A. Pop John H. Wilton Krystin M. Mantione Yun Li Kristopher M. Attwood Gissou Azabdaftari Yue Wu David S. Watt Elizabeth M. Wilson James L. Mohler

Androgen deprivation therapy (ADT) is palliative and prostate cancer (CaP) recurs as lethal castration-recurrent/resistant CaP (CRPC). One mechanism that provides CaP resistance to ADT is primary backdoor androgen metabolism, which uses up to four 3α-oxidoreductases to convert 5α-androstane-3α,17β-diol (DIOL) to dihydrotestosterone (DHT). The goal was to determine whether inhibition of 3α-oxido...

2015

A. Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin) B. Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin) C. Interstitial laser coagulation of the prostate (ILCP) D. Laser prostatectomy E. Laser based procedures including contact laser ablation of the prostate (CLAP), holmium laser procedures of the prostate (HoLAP, ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید